New atrial fibrillation on the ward is decided by two questions from NICE NG196: is the patient haemodynamically unstable, and did it start less than 48 hours ago. Instability means emergency electrical cardioversion without delaying for anticoagulation; a stable patient with onset under 48 hours can have rate or rhythm control, and one with onset over 48 hours or uncertain has rate control while anticoagulation is arranged. For a CT1 anaesthetics candidate the station is about finding the cause, choosing the drug, and knowing that the post-operative patient's AF is usually a symptom of something else.

Key takeaways

  • NICE NG196 (2021) says to carry out emergency electrical cardioversion, without delaying to achieve anticoagulation, in people with life-threatening haemodynamic instability caused by new-onset atrial fibrillation.
  • Without instability, offer either rate or rhythm control if onset is less than 48 hours, and rate control if onset is more than 48 hours or uncertain.
  • Initial rate control is a standard beta-blocker (not sotalol) or a rate-limiting calcium-channel blocker, diltiazem or verapamil; digoxin monotherapy is considered for sedentary patients with non-paroxysmal AF.
  • In suspected concomitant acute decompensated heart failure, seek senior specialist input on beta-blockers and do not use calcium-channel blockers.
  • Pharmacological cardioversion is flecainide or amiodarone if there is no structural or ischaemic heart disease, and amiodarone if there is; AF lasting over 48 hours needs 3 weeks of therapeutic anticoagulation before elective cardioversion.
  • Anticoagulate with a direct-acting oral anticoagulant at a CHA2DS2-VASc of 2 or above, consider it for men scoring 1, and use ORBIT to assess bleeding risk.

How do you recognise new atrial fibrillation on the ward?

You recognise new atrial fibrillation from an irregularly irregular pulse confirmed on a 12-lead ECG with no P waves, and you decide within the first minute whether it is causing life-threatening haemodynamic instability, because that decision sets everything else.

On the ward it presents as palpitations, a fast irregular rate on the observations chart, breathlessness, chest pain, or a fall in blood pressure after surgery. In the post-operative patient it is more often a sign than a diagnosis.

So the second question is why. Sepsis, hypovolaemia, bleeding, electrolyte disturbance, pain, hypoxia, pulmonary embolism, myocardial ischaemia and thyroid disease all precipitate atrial fibrillation, and treating the rate without treating the cause fails.

In practice, the history that matters most is timing. NG196 splits the acute pathway at 48 hours from onset, and 'uncertain' counts as over 48 hours. Ask when the palpitations started, and look at the previous ECGs.

What is the A to E and first-hour management of new atrial fibrillation?

The first hour of new atrial fibrillation is A to E with monitoring and a 12-lead ECG, the instability decision, correction of the precipitant and the electrolytes, and then the rate-or-rhythm choice by the 48-hour rule.

Airway, breathing and circulation

  • Oxygen only to the BTS target of 94 to 98 per cent, and a search for hypoxia or a chest cause such as pneumonia or embolism.
  • Continuous monitoring, a 12-lead ECG, blood pressure and signs of shock, heart failure, ischaemia or syncope, which are the features of life-threatening instability.
  • Intravenous access, bloods including potassium, magnesium, calcium, thyroid function, full blood count, renal function and troponin if there is chest pain.
  • Fluid resuscitation if hypovolaemic, and a review of the drug chart, the fluid balance and the wound or drains after surgery.

Disability, exposure and the cause

  • Temperature and a sepsis screen, because infection is the commonest ward precipitant.
  • Pain assessment and analgesia.
  • A chest X-ray and, where the story fits, investigations for pulmonary embolism.
  • Ask about alcohol, previous AF, anticoagulant history and any recent cardiac surgery or procedure.

What is the 48-hour rule, and how do CHA2DS2-VASc and ORBIT fit in?

The 48-hour rule in NG196 is that a stable patient whose atrial fibrillation started less than 48 hours ago may be offered rate or rhythm control, while onset over 48 hours or uncertain means rate control, because cardioversion after 48 hours without anticoagulation risks embolising an atrial thrombus.

According to NG196, when duration is over 48 hours or uncertain and long-term rhythm control is planned, cardioversion is delayed until the patient has been on therapeutic anticoagulation for a minimum of 3 weeks, with rate control in the meantime. Transoesophageal echo-guided cardioversion is an equally effective alternative for those who need a shorter run-in.

CHA2DS2-VASc is the stroke-risk score NG196 uses to decide anticoagulation. Offer a direct-acting oral anticoagulant at a score of 2 or above, consider it for men scoring 1, and do not anticoagulate people under 65 whose only risk factor is their sex.

ORBIT is the bleeding-risk tool NG196 now prefers, because it predicts absolute bleeding risk more accurately than HAS-BLED. The guideline is clear that a high bleeding score prompts risk reduction, such as controlling blood pressure and correcting anaemia, rather than withholding anticoagulation.

What is the definitive management of new atrial fibrillation?

Definitive management of new atrial fibrillation is treatment of the precipitant, rate control with a beta-blocker or rate-limiting calcium-channel blocker, rhythm control by drug or electricity where the 48-hour rule and the heart allow, and anticoagulation decided by CHA2DS2-VASc and ORBIT before discharge.

Rate control under NG196

  • First line is a standard beta-blocker other than sotalol, or diltiazem or verapamil, chosen on symptoms, heart rate, comorbidities and preference.
  • In heart failure, follow the chronic heart failure guideline: beta-blocker, and avoid the rate-limiting calcium-channel blockers.
  • Digoxin monotherapy is considered for non-paroxysmal AF in sedentary patients or where other drugs are unsuitable.
  • If monotherapy fails, combine any two of a beta-blocker, diltiazem and digoxin. Amiodarone is not for long-term rate control.

Rhythm control under NG196

For new-onset AF treated with rhythm control, NG196 allows either pharmacological or electrical cardioversion depending on circumstances and resources. Pharmacological cardioversion is a choice of flecainide or amiodarone without structural or ischaemic heart disease, and amiodarone alone with structural heart disease. Class 1c drugs such as flecainide are not offered in ischaemic or structural heart disease.

AF that has persisted over 48 hours is cardioverted electrically rather than pharmacologically, and amiodarone may be started 4 weeks before and continued up to 12 months after to maintain sinus rhythm. Anyone whose treatment fails is referred within 4 weeks.

When do you escalate new atrial fibrillation, and who do you call?

You escalate new atrial fibrillation immediately if there is life-threatening haemodynamic instability, and the call is to the medical registrar, the cardiac arrest or peri-arrest team and the anaesthetist, because emergency electrical cardioversion needs sedation and a team, and NG196 says not to delay it for anticoagulation.

For a stable patient the escalation is to the medical registrar for the rate-or-rhythm decision and to cardiology where cardioversion is planned. NG196 also says to seek senior specialist input on beta-blockers where there is suspected acute decompensated heart failure, and never to use calcium-channel blockers there.

As the anaesthetic CT1, you are the sedation for the cardioversion and the person asked whether a patient in new AF can go to theatre. Both are consultant conversations: a new arrhythmia is a reason to postpone an elective case, and the surgeon needs to hear that from you and your consultant together.

However, most ward AF is not peri-arrest. Escalate the cause: the bleeding, the sepsis, the potassium. A rate that settles once the pain is treated and the fluids are in was never a cardiology problem.

What is the human-factors and reflective-practice angle in new atrial fibrillation?

The human-factors angle in new atrial fibrillation is treating the number: a rate of 140 gets a beta-blocker while the septic, hypovolaemic or bleeding cause is missed, and the blood pressure falls further.

A good answer says the first drug for post-operative AF is often a fluid bolus, an antibiotic or analgesia, and that rate control is added once the cause is being treated and the pressure allows.

Reflective practice wants an example. Many candidates have seen a patient cardioverted at 72 hours without anticoagulation, or a calcium-channel blocker given to a patient in heart failure. Describe what happened, what the guideline says, and what you now check before prescribing.

Working under pressure is the unstable patient at 3 am: pads on, sedation drawn up, an anaesthetist on the way, and a decision that cannot wait for the anticoagulation clinic.

What are the common mistakes candidates make with new atrial fibrillation?

The commonest mistake with new atrial fibrillation at interview is cardioverting a stable patient with onset over 48 hours without anticoagulation, or delaying cardioversion in an unstable one to arrange it. NG196 is explicit about both.

  • Rate-controlling before looking for sepsis, bleeding, hypovolaemia or an electrolyte problem.
  • Giving diltiazem or verapamil to a patient in heart failure, which NG196 says not to do.
  • Choosing flecainide in a patient with ischaemic or structural heart disease.
  • Using amiodarone for long-term rate control, which NG196 says not to offer.
  • Quoting HAS-BLED as the bleeding tool; NG196 asks for ORBIT.
  • Forgetting that 'uncertain onset' is treated as more than 48 hours.

How this comes up at the CT1 anaesthetics interview

New atrial fibrillation comes up at the CT1 anaesthetics interview as a post-operative ward call, a pre-operative ECG or a peri-arrest patient in the clinical judgement station, which ANRO marks on clinical judgement and decision making, reflective practice and working under pressure.

Clinical judgement is stable or unstable, the 48-hour rule and the cause. Decision making is cardiovert or control, and whether tomorrow's list goes ahead. Reflective practice is the AF you treated as a rate rather than a symptom. Working under pressure is the sedated cardioversion at night.

The panel will commonly drop the blood pressure mid-answer. The anaestheticinterview bank rehearses that turn with AI-marked spoken practice across its 340 questions, scoring whether the answer changes to emergency cardioversion when the patient becomes unstable.